Efficacy and Toxicity of CD19 Chimeric Antigen Receptor T Cell Therapy for Lymphoma in Solid Organ Transplant Recipients: A Systematic Review and Meta-AnalysisSamuel Yamshon, Tsiporah B. Shore, Caitlin Gribbin et al.|Transplantation and Cellular Therapy|2023Cited by 10
Nine-year follow-up of lenalidomide plus rituximab as initial treatment for mantle cell lymphomaSamuel Yamshon, Jia Ruan, Gui Zhen Chen et al.|Blood Advances|2023Cited by 10
MRD-Driven Time-Limited Therapy of Acalabrutinib and Lenalidomide Plus Rituximab (ALR) or Obinutuzumab (ALO) in Patients with Treatment-Naïve Mantle Cell Lymphoma: Phase 2 Trial Outcomes with MRD and cfDNA AnalysesJia Ruan, Peter Martin, David A. Bond et al.|Blood|2024Cited by 7
Novel treatment for mantle cell lymphoma – impact of BTK inhibitors and beyondCaitlin Gribbin, Jia Ruan, Jane Chen et al.|Leukemia & lymphoma/Leukemia and lymphoma|2023Cited by 6
MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphomaJia Ruan, Peter W. Martin, Brittany Hobbie et al.|Blood Advances|2025Cited by 3